Mallia Therapeutics Header
Mallia secures an Early-Stage Innovation Award at BioVaria

Dr. Manfred Gröppel convinced a jury of technology transfer professionals with a pitch presentation of our approach to combatting hairloss with the soluble human protein sCD83. Our preclinical results with a topical formulation of sCD83 show that its dual mode of action can lead to substantial hair growth. In addition, unlike marketed treatments, sCD83 can induce the activation and formation of new hair follicles while also avoiding systemic side effects.

Thank you BioVaria for a great event in Munich!

<< back to overview